<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568282</url>
  </required_header>
  <id_info>
    <org_study_id>LUN0017</org_study_id>
    <secondary_id>96710</secondary_id>
    <secondary_id>LUN0017</secondary_id>
    <secondary_id>4086</secondary_id>
    <nct_id>NCT00568282</nct_id>
  </id_info>
  <brief_title>Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients</brief_title>
  <official_title>Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine whether we can identify human lung cancer tumor
      cells in the peripheral blood of lung cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether we can identify lung cancer cells
      circulating in the peripheral blood of lung cancer patients using cell surface markers found
      on cancer cells such as CD44 and epithelial specific antigen.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2007</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">March 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">219</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phlebotomy</intervention_name>
    <description>Standard of care</description>
    <other_name>blood draw</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stage NSCLC who are either newly diagnosed, or who have evidence of
        disease progression.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases):

          1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically
             confirmed NSCLC

          2. Patients must be newly diagnosed (untreated) or have evidence of disease progression
             at the time of sample collection

          3. ability to sign informed consent

          4. at least 18 years of age

        Inclusion Criteria (Controls):

          1. no known prior or active malignancy

          2. ability to sign informed consent

          3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than
             non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any
             other cancer other than non-melanoma skin cancer within the last 5 years

        2. pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather A. Wakelee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

